ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿öÅ©Ç÷ο캰, ¼­ºñ½ºº°, Ä¡·á ¿µ¿ªº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2033³â)
Small Molecule Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow (Target Identification & Screening, Preclinical Development), By Service, By Therapeutics Area, By End Use, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1790277
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,359,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,764,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,573,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå °³¿ä

ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 45¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2033³â¿¡´Â 106¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 10.03%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. R&D ºñ¿ë Áõ°¡, ÀǾàǰ °³¹ß ¼ö¿ä Áõ°¡, °¡»ó ÀǾàǰ ¸ðµ¨·ÎÀÇ ÀüȯÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

±âŸ ½ÃÀå ¼ºÀå ¿äÀÎÀ¸·Î´Â µî·Ï ¿¬±¸ ¼ö Áõ°¡, ÀúºÐÀÚ ÀǾàǰÀÇ ½ÂÀÎ È®´ë, ÀÇ·á ±â¼ú ¹ßÀü, ¿¬±¸ ´ë»ó Áúȯ Áõ°¡, »õ·Î¿î Ä¡·á¹ýÀÇ Çʿ伺 µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÇöÀç ÀúºÐÀÚ ÀǾàǰÀº Á¦¾à »ê¾÷ÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀúºÐÀÚ¸¦ Ư¡À¸·Î ÇÏ´Â ÀÌ À¯±â È­ÇÕ¹°Àº Ä¡·áÁ¦·Î¼­ ¸î °¡Áö ÀåÁ¡À» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ ºÐÀÚµéÀº ³ôÀº °æ±¸ »ýü ÀÌ¿ë·ü, ÀûÀÀ °¡´ÉÇÑ Åõ¿© ¿ä¹ý, ¼¼Æ÷ ³» °æ·Î¿¡ °ü¿©ÇÏ´Â ´É·Â µîÀÇ ÀÌÁ¡À» Á¦°øÇϸç, ƯÈ÷ ¾Ï, °¨¿°¼º Áúȯ, ½Å°æ Áúȯ µî ´Ù¾çÇÑ Áúȯ¿¡ Àû¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ½Å¾à°³¹ßÀº ÀÌ·¯ÇÑ ÀúºÐÀÚ ÀǾàǰ °³¹ß¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖÀ¸¸ç, È¿°úÀûÀÎ Ä¡·á¹ýÀ» ¼ö¸³Çϰí R&D ÆÄÀÌÇÁ¶óÀÎÀ» °¡¼ÓÈ­Çϱâ À§ÇÑ º¹ÀâÇÑ ´Ü°è¿Í ÃÖ÷´Ü ±â¼úÀ» Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ¸¹Àº Á¦¾à»ç ¹× ¹ÙÀÌ¿À Á¦¾à»çµéÀº Ç¥Àû ¹ß±¼, È÷Æ®¿¡¼­ ¸®µå±îÁöÀÇ ÇÁ·Î¼¼½º, ¸®µå ÃÖÀûÈ­, ½ÂÀÎ ÇÁ·Î¼¼½º µî ½Å¾à°³¹ß Ãʱ⠴ܰ踦 °ü¸®ÇÏ´Â Àü¹®¼ºÀ» °®Ãá ¾Æ¿ô¼Ò½Ì ±â¾÷°úÀÇ Á¦ÈÞ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â ¹Ì±¹ FDA ÀǾàǰ Æò°¡ ¿¬±¸¼¾ÅÍ´Â 32°³ÀÇ È­ÇÐÀû ½Çü¿Í 18°³ÀÇ »ý¹°ÇÐÀû ½Çü·Î ±¸¼ºµÈ 50°³ÀÇ »õ·Î¿î ºÐÀÚ ½Çü¸¦ ½ÂÀÎÇß½À´Ï´Ù. ¶ÇÇÑ, NCEs Áß ÀúºÐÀÚ°¡ 91%(31°³ ǰ¸ñ)¸¦ Â÷ÁöÇÏ¸ç °¡Àå Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖÀ¸¸ç, ³ª¸ÓÁö ÀǾàǰÀº ÆéŸÀ̵å¿Í ÇÙ»êÀÔ´Ï´Ù.

¶ÇÇÑ, Á¦¾à »ê¾÷¿¡¼­ ¾Æ¿ô¼Ò½ÌÀº ¼º°øÀûÀÎ ÀǾàǰ °³¹ß ¹× »ó¾÷È­¿¡ ÇʼöÀûÀÎ ±âŸ ¿ª·®À» È®º¸ÇÒ ¼ö ÀÖ´Ù´Â ÀÌÁ¡À» ±â¾÷µéÀÌ ÀνÄÇϸ鼭 ´õ¿í ź·ÂÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¾Æ¿ô¼Ò½ÌÀº Àü¹® Áö½Ä Á¦°ø, Çö±Ý È帧 °ü¸® °³¼±, ÅõÀÚ À§Çè °¨¼Ò µî Á¦Á¶¿¡ ÀÖ¾î Å« ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, Ãʱ⠴ܰèÀÇ ±â¼úÀ̳ª Á¦Ç°¿¡ ºñ¿ëÀÌ ¸¹ÀÌ µå´Â ÀÚü ¿ª·®À» °³¹ßÇÏ´Â °ÍÀº °³¹ß ±â°£ µ¿¾È »ó´çÇÑ ¸®½ºÅ©¸¦ ¼ö¹ÝÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÀ¯·Î ¾Æ¿ô¼Ò½ÌÀº Á¦Ç° Çõ½ÅÀÇ À§ÇèȸÇǸ¦ À§ÇÑ »õ·Î¿î ´ë¾ÈÀ¸·Î ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¾÷µéÀº Á¾Á¾ ÇöÀç¿Í ¹Ì·¡ÀÇ Á¦Ç° Á¦°ø ¹× ½ÃÀå ħÅõ¿¡ ÇÊ¿äÇÑ ±Ô¸ð¸¦ °áÁ¤ÇØ¾ß ÇÏ´Â ¹®Á¦¿¡ Á÷¸éÇÏ¿© ÀÚü Á¦Á¶ ¼³°è ¹× ±Ô¸ð È®ÀåÀ» º¹ÀâÇÏ°Ô ¸¸µå´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±× °á°ú, ¾Æ¿ô¼Ò½ÌÀº Á¦Ç° Çõ½ÅÀ» À§ÇØ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ¾ú½À´Ï´Ù.

¶ÇÇÑ, Çõ½ÅÀûÀÎ ±â¼ú, ¸¸¼º Áúȯ ¹× °¨¿°¼º Áúȯ Áõ°¡, »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀΰøÁö´É, ¸Ó½Å·¯´×, °í¼º´É ½ºÅ©¸®´× µîÀÇ ¹ßÀüÀº È÷Æ® È­ÇÕ¹° ½Äº° ¹× ¸®µå È­ÇÕ¹° ÃÖÀûÈ­ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­ÇÏ¿© ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤¹ÐÀÇ·á¿Í AI¸¦ Ȱ¿ëÇÑ ½ºÅ©¸®´× ±â¹ýÀÇ ¹ßÀüÀº ½Å¾à°³¹ß °úÁ¤ÀÇ È¿À²¼ºÀ» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, ¾à¹° ¼³°è, ¿¹Ãø ¸ðµ¨¸µ, Á¤¹ÐÀÇ·áÀÇ ¹ßÀüÀº ½Å¾à °³¹ß Ãʱ⠴ܰ迡¼­ ¾Æ¿ô¼Ò½Ì ÆÄÆ®³ÊÀÇ ±â¿©µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ÃßÁ¤ ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : ¿öÅ©Ç÷ο캰, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : ¼­ºñ½ºº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : Ä¡·á ¿µ¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå ÀúºÐÀÚ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå °æÀï ±¸µµ

Á¦9Àå ÁÖ¿ä Ãßõ »çÇ×

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Small Molecule Drug Discovery Outsourcing Market Summary

The global small molecule drug discovery outsourcing market size was estimated at USD 4.55 billion in 2024, and is projected to reach USD 10.62 billion by 2033, growing at a CAGR of 10.03% from 2025 to 2033. Rising research and development expenses, an increasing need for drug development, and a transition toward virtual pharmaceutical models drive the market.

Some other factors contributing to market growth are a rising number of registered studies, growing approval of small molecule drugs, advancements in medical technology, an upsurge in diseases under investigation, and the imperative for novel treatments. Currently, small molecule drugs have been the cornerstone of the pharmaceutical industry. These organic compounds, characterized by their low molecular weight, offer several advantages as therapeutic agents. These molecules provide advantages such as high oral bioavailability, adaptable dosing regimens, and the capability to engage intracellular pathways, making them applicable to a broad spectrum of diseases, particularly in areas like cancer, infections, and neurological disorders.

Besides, drug discovery plays a crucial role in developing these small molecule drugs, encompassing complex stages and cutting-edge technologies to formulate effective therapies and accelerate R&D pipelines. Thus, many pharmaceutical and biopharmaceutical companies are increasingly partnering with outsourcing companies specializing in the expertise to manage early discovery phases, including target identification, hit-to-lead processes, lead optimization, and the approval process. For instance, in 2024, the U.S. FDA Center for Drug Evaluation and Research approved 50 new molecular entities, consisting of 32 chemical entities & 18 biologic entities. Besides, of the NCEs, small molecules gained major attention and share, making up 91% (31 drugs), with the remaining drugs comprising peptides and nucleic acids.

Moreover, outsourcing in the pharmaceutical industry is gaining momentum as companies recognize the benefits of acquiring additional competencies essential for successful drug development and commercialization. Outsourcing provides specialized expertise, helps improve cash flow management, and offers significant manufacturing advantages, including reducing investment risks. Besides, developing costly in-house capabilities for early-stage technologies and products involves considerable risks throughout development. These factors have led to outsourcing as an emerging risk-averse alternative for product innovations. Moreover, companies often face challenges in determining the necessary scale for current and future product offerings or market penetration, complicating the design and scaling of in-house manufacturing. As a result, outsourcing has become a preferred option for product innovation.

Furthermore, innovative technologies, the rising prevalence of chronic and infectious diseases, and the growing need for new therapies support market growth. Advances such as artificial intelligence, machine learning, and high-throughput screening are streamlining the hit identification and lead optimization processes, supporting the market growth. Also, the advancement of precision medicine and AI-driven screening methods has further enhanced the efficiency of the discovery process. Similarly, advancements in drug design, predictive modeling, and precision medicine are enhancing the contributions of outsourcing partners in the early stages of drug discovery and development. Such factors are expected to drive the market growth over the estimated time period.

Global Small Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, end use, and region:

Table of Contents

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Small Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope

Chapter 4. Small Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

Chapter 5. Small Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

Chapter 6. Small Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

Chapter 7. Small Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

Chapter 8. Small Molecule Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

Chapter 9 Key Recommendations

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â